Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Posts Flat Q4 Revenues

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PerkinElmer reported after the close of the market Thursday that its fourth-quarter revenues were essentially flat with Q4 2008 but managed to beat analysts' consensus estimate.

The Waltham, Mass.-based firm generated total revenues of $498.3 million for the three-month period ended Jan. 3, 2010, compared to $500 million in sales for the fourth quarter of 2008. It noted that currency translation and acquisitions had a favorable impact on revenues of 4 percent and 1 percent, respectively.

Sales for its Human Health segment were $194.2 million, up slightly from $193.9 million, while sales for its Environmental Health segment were 4304.1 million versus $306 million for Q4 2008.

PerkinElmer's profit for the quarter was $39.9 million, or $.34 per share, compared to $30.7 million, or $.26 per share, for Q4 2008. On an adjusted basis, its EPS was $.43 versus $.46.

PerkinElmer beat analysts' consensus estimates for revenues of $479.5 million and EPS of $.41.

The firm's R&D spending increased 9 percent to $27.6 million from $25.3 million, and its SG&A spending increased 7 percent to $129.7 million from $121 million.

For full-year 2009, PerkinElmer brought in total revenues of $1.8 billion compared to $1.96 billion for 2008. Its Human Health segment had sales of $736.5 million versus $774.6 million for 2008, while its Environmental Health segment had sales of $1.08 billion, down from $1.19 billion.

Its full-year net income was $85.6 million, or $.73 per share, down from $126.4 million, or $1.07 per share. On an adjusted basis, its EPS was $1.27, down from $1.41.

PerkinElmer finished the year with cash and cash equivalents of $179.7 million.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.